Therapeutics and Clinical Risk Management (Feb 2022)

Development and Validation of a Clinical and Laboratory-Based Nomogram for Predicting Coronary Microvascular Obstruction in NSTEMI Patients After Primary PCI

  • Liu T,
  • Wang C,
  • Wang L,
  • Shi X,
  • Li X,
  • Chen J,
  • Xuan H,
  • Li D,
  • Xu T

Journal volume & issue
Vol. Volume 18
pp. 155 – 169

Abstract

Read online

Tao Liu,1,* Chaofan Wang,1,* Lili Wang,1 Xiangxiang Shi,2 Xiaoqun Li,2 Junhong Chen,1 Hoachen Xuan,1 Dongye Li,1 Tongda Xu1 1Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People’s Republic of China; 2Department of General Practice, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Tongda Xu; Dongye Li, Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People’s Republic of China, Email [email protected]; [email protected]: Cardiac microvascular obstruction (CMVO) remains a severe complication in non-ST elevation myocardial infarction (NSTEMI) patients with reperfusion therapy. We aimed at developing and validating the nomogram to predict the possibility of CMVO after primary percutaneous coronary intervention (PCI) by integrating clinical and laboratory-based information.Methods: A total of 325 patients undergoing primary PCI for NSTEMI were recruited and divided into the training cohort (n=226) and the validating cohort (n = 99). The development of the nomogram was based on independent predictors of CMVO, and these variables were selected by multivariable logistic regression analysis.Results: Independent predictors contained in nomogram were identified by multivariable logistic regression analysis, and these independent predictors included neutrophils (OR 1.166, 95% CI 1.044– 1.303, P< 0.01), hemoglobin (OR 1.037, 95% CI 1.013– 1.062, P< 0.01), triglyceride (OR 1.343, 95% CI 1.059; 1.704, P=0.015), Killip grade (OR 2.190, 95% CI 1.065– 4.503, P=0.033), high thrombus load (OR 3.146, 95% CI 1.424– 6.952, P< 0.01), no-reflow (OR 3.142, 95% CI 1.419– 6.955, P< 0.01) and ischemic postconditioning (OR 0.445, 95% CI 0.209– 0.944, P=0.035). The nomogram accurately predicted the presentation of CMVO in both the training set and validating set (AUC, 0.835 and 0.881, respectively). The results predicted by nomogram were confirmed to be highly consistent with the results of DE-CMR, both the training and validating cohorts, by Calibration plot and Hosmer-Lemeshow test. Decision curve analysis (DCA) also suggested that the nomogram was applicable in the clinic.Conclusion: The nomogram showed good performance in predicting CMVO, and it could help clinicians optimize the clinical treatments to improve the prognosis of NSTEMI patients.Keywords: non-ST elevation myocardial infarction, cardiac microvascular obstruction, primary percutaneous coronary intervention, nomogram, prediction model

Keywords